Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Atsushi Masamune

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7184-7282; OpenAlex author ID A5044706381, A5108466876. Sources: OpenAlex.

Their work

Papers
88 (first author 13, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
265
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 5 papers · 2014: 5 papers · 2015: 4 papers · 2016: 3 papers · 2017: 6 papers · 2018: 4 papers · 2019: 6 papers · 2020: 5 papers · 2021: 5 papers · 2022: 8 papers · 2023: 4 papers · 2024: 5 papers · 2025: 5 papers · 2026: 18 papers

Papers 50 of 88

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  3. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  4. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  5. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Last author DOI 10.1016/j.gie.2026.05.032↗
  6. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117071↗
  7. Spatial Profiling Identified Senescent Cancer-Associated Fibroblasts Localized in the Border Region of Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2026.101808↗
  8. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Co-author DOI 10.1016/j.pan.2026.03.007↗
  9. Utility of longitudinal changes in CA19-9 for detection of pancreatic ductal adenocarcinoma in patients with benign pancreatic diseases. Last author DOI 10.1016/j.pan.2026.10.007↗
  10. p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. Co-author DOI 10.1038/s41417-025-00989-3↗
  11. High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Co-author DOI 10.1038/s41598-026-56838-2↗
  12. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Last author DOI 10.1097/mpa.0000000000002600↗
  13. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Last author DOI 10.1097/mpa.0000000000002694↗
  14. SUSD2 Promotes Metastasis and Primary Tumor Growth in Pancreatic Cancer Cells via Integrin-FAK Signaling Activation. Co-author DOI 10.1111/cas.70318↗
  15. Type I Collagen Increases Survivin Expression in Pancreatic Cancer Cells. Last author DOI 10.1620/tjem.2026.j084↗
  16. Diabetes Trajectory and Pancreatic Cancer Detection in Patients with Diabetes: A Nationwide Survey Through Japan Diabetes Society-Certified Facilities. Co-author DOI 10.3390/cancers18182995↗
  17. Cancer‑associated fibroblast‑derived extracellular vesicles promote pancreatic cancer progression via the RAP1B/ANLN axis. Co-author DOI 10.3892/or.2026.9182↗
  18. Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
  19. Collagen Signaling via DDR1 Exacerbates Barriers to Macromolecular Drug Delivery in a 3D Model of Pancreatic Cancer Fibrosis. Co-author DOI 10.1002/smll.202506926↗
  20. A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-025-02193-0↗
  21. Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. Co-author DOI 10.1038/s44318-025-00570-6↗
  22. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  23. Treatment of Pancreatic Cancer Using Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Combination with Anticancer Chemotherapeutic D… Co-author DOI 10.3390/cancers17091584↗
  24. Rupture of ectopic varices of the ascending colon occurring after pancreatic cancer surgery: A case report and literature review. Last author DOI 10.1002/deo2.255↗
  25. Targeting ROCK2 improves macromolecular permeability in a 3D fibrotic pancreatic cancer microenvironment model. Co-author DOI 10.1016/j.jconrel.2024.03.041↗
  26. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Co-author DOI 10.1111/cas.16087↗
  27. Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo. Co-author DOI 10.1136/rapm-2023-104511↗
  28. A Role for Periostin Pathological Variants and Their Interaction with HSP70-1a in Promoting Pancreatic Cancer Progression and Chemoresistance. Co-author DOI 10.3390/ijms252313205↗
  29. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  30. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.modpat.2023.100102↗
  31. Author Correction: Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymph… Co-author DOI 10.1038/s41598-023-40226-1↗
  32. Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer. Co-author DOI 10.1097/j.pain.0000000000002852↗
  33. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bja.2021.12.042↗
  34. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  35. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  36. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Last author DOI 10.1038/s41598-022-08083-6↗
  37. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer. Co-author DOI 10.1038/s41598-022-14297-5↗
  38. Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression. Co-author DOI 10.1038/s41598-022-16671-9↗
  39. HIF-1 and NRF2; Key Molecules for Malignant Phenotypes of Pancreatic Cancer. Last author DOI 10.3390/cancers14020411↗
  40. Senescent Human Pancreatic Stellate Cells Secrete CXCR2 Agonist CXCLs to Promote Proliferation and Migration of Human Pancreatic Cancer AsPC-1 and MIAPaCa-2 Ce… Last author DOI 10.3390/ijms23169275↗
  41. Effective apparent diffusion coefficient parameters for differentiation between mass-forming autoimmune pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02795-x↗
  42. Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression. Last author DOI 10.1124/jpet.121.000744↗
  43. Abnormal Findings on "T1WI or DWI or MRCP:" An Effective Boolean Interpretation Model in Discriminating Small Pancreatic Ductal Adenocarcinoma from Control Gro… Co-author DOI 10.25259/jcis_158_2021↗
  44. Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study. Last author DOI 10.3390/diagnostics11091693↗
  45. Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition. Last author DOI 10.3390/ijms22041870↗
  46. Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements. Co-author DOI 10.1016/j.biomaterials.2020.120077↗
  47. Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Co-author DOI 10.1097/j.pain.0000000000001997↗
  48. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  49. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer. Last author DOI 10.1620/tjem.252.353↗
  50. Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct. Last author DOI 10.1620/tjem.252.63↗

Closest collaborators

The 25 strongest of 265 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shin Hamada · 39 shared papers, 2012–2026 · strength 4.50
  2. Michiaki Unno · 20 shared papers, 2013–2026 · strength 3.11
  3. Ryotaro Matsumoto · 11 shared papers, 2020–2026 · strength 1.99
  4. Masamichi Mizuma · 11 shared papers, 2016–2026 · strength 1.97
  5. Tetsuya Takikawa · 14 shared papers, 2012–2026 · strength 1.78
  6. Tooru Shimosegawa · 25 shared papers, 2012–2026 · strength 1.66
  7. Kazuhiro Kikuta · 14 shared papers, 2012–2026 · strength 1.54
  8. Sohei Satoi · 9 shared papers, 2016–2026 · strength 1.38
  9. Yoshifumi Takeyama · 6 shared papers, 2023–2026 · strength 1.17
  10. Shuichi Aoki · 5 shared papers, 2024–2026 · strength 1.16
  11. Toru Furukawa · 7 shared papers, 2018–2026 · strength 1.06
  12. Masahiro Iseki · 6 shared papers, 2019–2026 · strength 1.01
  13. Shin Miura · 10 shared papers, 2013–2026 · strength 1.00
  14. Yoshiki Hirooka · 9 shared papers, 2016–2026 · strength 0.98
  15. Kohei Nakata · 4 shared papers, 2026 · strength 0.97
  16. Ken Shirabe · 5 shared papers, 2019–2026 · strength 0.96
  17. Hiroyoshi Y. Tanaka · 5 shared papers, 2019–2026 · strength 0.93
  18. Mitsunobu R. Kano · 5 shared papers, 2019–2026 · strength 0.93
  19. Takao Itoi · 6 shared papers, 2016–2026 · strength 0.91
  20. Shinichi Egawa · 6 shared papers, 2013–2026 · strength 0.86
  21. Makoto Sano · 5 shared papers, 2020–2026 · strength 0.85
  22. Yoshimi Ichimaru · 5 shared papers, 2020–2026 · strength 0.85
  23. Hideaki Ijichi · 5 shared papers, 2020–2026 · strength 0.85
  24. Kazuichi Okazaki · 5 shared papers, 2019–2026 · strength 0.78
  25. Naoki Yoshida · 8 shared papers, 2013–2022 · strength 0.73

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.